Pharmacotherapy of ovarian hyperstimulation syndrome

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 15, 2010, Pages 2527-2534

  Genazzani, Andrea Riccardo ^a   Monteleone, Patrizia ^a   Papini, Francesca ^a   Artini, Paolo Giovanni ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

ART; OHSS; PCOS; Stimulation; Therapy

Indexed keywords

CHORIONIC GONADOTROPIN; CODEINE; DEXTRAN; DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; GONADORELIN ANTAGONIST; GONADOTROPIN; HEPARIN; HETASTARCH; HUMAN ALBUMIN; HUMAN MENOPAUSAL GONADOTROPIN; LOW MOLECULAR WEIGHT HEPARIN; MANNITOL; METFORMIN; OPIATE; PARACETAMOL; PLACEBO; QUINAGOLIDE; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLOATING; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; EMBOLISM PREVENTION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LIVER DYSFUNCTION; LOW DRUG DOSE; MOLECULAR MECHANICS; OCCLUSIVE CEREBROVASCULAR DISEASE; OLIGURIA; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PARACENTESIS; PATHOPHYSIOLOGY; PLEURA EFFUSION; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ACETAMINOPHEN; ANIMALS; FEMALE; HORMONE ANTAGONISTS; HUMANS; METFORMIN; OVARIAN HYPERSTIMULATION SYNDROME; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 77957038364     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.499359     Document Type: Review

References (62)

1. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006;27(2):170-207
2. Abramov Y, Elchalal U, Schenker JG. Severe OHSS: an epidemic of severe OHSS: a price we have to pay? Hum Reprod 1999;14(9):2181-2183
3. Enskog A, Henriksson M, Unander M, et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71(5):808-814
4. Whelan JG III, Vlahos ENF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;11(5):883-896
5. Golan A, Ron-El R, Hoffman A, et al. CASPI. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-40.4
6. Gianaroli L, Ferraretti AP, Magli EMC. Pathophysiology of ovarian hyperstimulation syndrome (OHSS). Volume 1. Serono fertility series; p.11-20.
7. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58(2):249-261
8. Daelemans C, Smits G, De Maertelaer V, et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab 2004;89(12):6310-6315
9. Pellicer A, Albert C, Mercader A, et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999;71(3):482-489
10. Niederberger V, Rottensteiner-Grohsmann C, Turnheim K, et al. Incidence of ovarian hyperstimulation syndrome in in-vitro-fertilization treatment over a period of 11 years. Wien Med Wochenschr. 1995;145(23):642-645
11. Qasim SM, Karacan M, Kemmann E. An eight year review of hospitalization for ovarian hyperstimulation syndrome. Clin Exp Obstet Gynecol 1997;24(2):49-52
12. Agrawal R, Holmes J, Jacobs HS. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis. Fertil Steril 2000;73(2):338-343
13. Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997;67(2):261-265
14. Goldsman MP, Pedram A, Dominguez CE, et al. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 1995;63(2):268-272
15. Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80(6):1967-1971
16. Albert C, Garrido N, Mercader A, et al. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 2002;8(5):409-418
17. Rizk B, Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod 1991;6(8):1082-1087
18. Zosmer A, Katz Z, Lancet M, et al. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril 1987;47(3):524-526
19. Ferraretti AP, Gianaroli L, Fiorentino EA. The ovarian hyperstimulation syndrome (OHSS): definition, clinical symptons, classification and incidence. Volume 1. Serono fertility series; 1997. p. 1-102
20. Royal college of obstetricians and gynaecologists. The management of ovarian hyperstimulation syndrome. Green-top Guideline No.5 September 2006
21. Balasch J, Carmona F, Llach J, et al. Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome. Hum Reprod 1990;5:348-351
22. Evbuomwan IO, Davison JM, Murdoch AP. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox. Fertil Steril 2000;74:67-72
23. Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1999;71:645-651 (Pubitemid 29149413)
24. Bates SM, Greer IA, Pabinger I, et al.; American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Edition. Chest 2008;133(6 Suppl):844S-886S
25. Golan A, Ron-El R, Herman A, et al. Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. Fertil Steril 1988;50(6):912-916
26. Brinsden PR, Wada I, Tan SL, et al. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995;102(10):767-772
27. Aboulghar MA, Mansour RT, Serour GI, et al. Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. Fertil Steril 1996;66(5):757-760
28. Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 1999;5(5):493-499
29. El-Sheikh MM, Hussein M, Fouad S, et al. Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 2001;94(2):245-249
30. Bider D, Menashe Y, Oelsner G, et al. Ovarian hyperstimulation syndrome due to exogenous gonadotropin administration. Acta Obstet Gynecol Scand 1989;68(6):511-514
31. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod 1992;7(3):320-327
32. Dale PO, Tanbo T, Abyholm T. In-vitro fertilization in infertile women with the polycystic ovarian syndrome. Hum Reprod 1991;6(2):238-241
33. MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod 1993;8(2):233-237
34. Lass A, Vassiliev A, Decosterd G, et al. Relationship of baseline ovarian volume to ovarian response in World Health Organization II anovulatory patients who underwent ovulation induction with gonadotropins. Fertil Steril 2002;78(2):265-269
35. Delvigne A, Vandromme J, Demeestere I, Leroy F. Unpredictable cases of complicated ovarian hyperstimulation in IVF. Int J Fertil Womens Med 1997;42(4):268-270
36. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85(1):112-120
37. Mansour R, Aboulghar M, Serour G, et al. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005;20(11):3167-3172
38. Tortoriello DV, McGovern PG, Colon JM, et al. Coasting does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertil Steril 1998;69(3):454-460
39. Sher G, Zouves C, Feinman M, Maassarani G. Prolonged coasting: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod 1995;10(12):3107-3109
40. Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod 2006;21(11):2830-2837
41. Aboulghar MA, Mansour RT, Amin YM, et al. A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online 2007;15(3):271-279
42. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010; In press
43. Aboulghar MA, Mansour RT, Amin YM, et al. Prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online 2007;15(3):271-279
44. Khattab S, Fotouh IA, Mohesn IA, et al. Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach. Reprod Biomed Online 2006;13(2):194-197
45. Tang T, Glanville J, Orsi N, et al. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006;21(6):1416-1425
46. Shoham Z, Weissman A, Barash A, et al. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril 1994;62(1):137-142
47. Jee BC, Suh CS, Kim YB, et al. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest 2010;70(1):47-54
48. Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome [review]. Cochrane Database Syst Rev 2002;(2):CD001302
49. Konig E, Bussen S, Sutterlin M, Steck T. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Hum Reprod 1998;13(9):2421-2424
50. Nargund G, Hutchison L, Scaramuzzi R, Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online 2007;14(6):682-685
51. Driscoll GL, Tyler JP, Hangan JT, et al. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod 2000;15(6):1305-1310
52. Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril 2004;82(4):841-846
53. Diedrich K, Ludwig M, Felberbaum RE. The role of gonadotrophin-releasing hormone antagonists in in vitro fertilization. Semin Reprod Med 2001;19:213-220
54. Babayof R, Margalioth EJ, Huleihel M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006;21(5):1260-1265
55. Engmann L, Diluigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89(1):84-91
56. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;12(2):159-168
57. Carizza C, Abdelmassih V, Abdelmassih S, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008;17(6):751-755
58. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147(11):5400-5411
59. Alvarez C, Alonso-Muriel I, Garcia G, et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22(12):3210-3214
60. Youssef MA, Van Wely M, Hassan MA, et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010; In press
61. Busso CE, Garcia-Velasco J, Gomez R, et al. Symposium: update on prediction and management of OHSS. Prevention of OHSS-dopamine agonists. Reprod Biomed Online 2009;19(1):43-51
62. Busso C, Fernandez-Sanchez M, Garcia-Velasco JA, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010;25(4):995-1004